| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
10% Owner | Director
2 companies
Robert I Tepper last filed a Form 4 in October 2017, as Director at KALA. The filings on record cover 2 companies.
At the last filing, the largest reported position was 29,516 shares of CTMX. The CTMX filings lean toward selling, a net 59,777 shares.
Robert I Tepper has 5 Form 4 filings on record from June 2017 to October 2017, across 2 companies: 10% Owner at CytomX Therapeutics (CTMX), 2017; Director at Kala Bio (KALA), 2017.
The 5 reported transactions were 3 open-market sales, 1 conversion and 1 option or other derivative award.
Counted by filing, the open-market trades come to no purchases and 3 sales worth about $1.2M.
The largest open-market sale was 24,777 shares of CTMX at an average $24.34 on October 4, 2017, about $603K.
Shares as reported in the last Form 4 for each company; the most recent is from October 2017. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.